Lower Extremity Arterial Disease (Fontaine Stages IIb-IV) Clinical Trial
Official title:
Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease
Late stage lower extremity arterial disease (LEAD) is known to be associated with hemodynamic
and metabolic abnormalities and very poor long-term prognosis. The prognostic value of
hemodynamic and metabolic profiling, however, is yet to be determined in this patient group.
Current study aims to identify novel prognostic biomarkers for better risk stratification of
late stage LEAD patients. It also allows to determine associations between
hemodynamic/arterial stiffness indices, low-molecular weight metabolites and other substances
(e.g. mediators of inflammation and bone-mineral metabolism, cardiac and kidney injury
biomarkers, microRNAs) thus providing potentially valuable insight into the pathogenic
mechanisms of this disease.
n/a